



Progress toward a Malaria Vaccine

Guest Editors:

Dr. Ganesh Ram Visweswaran

Seattle Children's Research
Institute, Center for Global
Infectious Diseases Research,
1900 9th Ave, Seattle, WA 98101,
USA

Dr. Kamalakannan Vijayan

Center for Global Infectious
Disease Research, 1900 9th Ave,
Seattle, WA 98101, USA

Deadline for manuscript
submissions:

closed (9 November 2022)

Message from the Guest Editors

Last year, the World Health organization (WHO) recommended RTS,S/AS01, a *Plasmodium falciparum* Circumsporozoite protein (CSP)-based pre-erythrocytic vaccine for children living at high-risk regions such as sub-Saharan Africa and other regions with high *P. falciparum* transmission. The vaccine has delivered a favorable safety profile and has shown significant reduction (30%) in malaria-prone areas. This has inspired several researchers around the world to develop advanced strategies and more efficient vaccines by identifying potential vaccine targets, different vaccine models (DNA, mRNA, Whole sporozoite, other subunit vaccines such as R21), immunization routes, different adjuvants, various vaccine carriers, etc., to achieve the WHO's target of eliminating malaria by 2030. The significance of this Special Issue is to set a common platform for researchers working in advanced malaria vaccine development areas as mentioned in the scope of the Special Issue. We aim to cover most topics related to vaccine development, new targets, different vaccines, animal models, vaccine efficacy and safety profiles, and so on and so forth.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com